The role of LILRB4 in interacting with tumour-associated macrophages and its negative regulation of immune responses in tumours highlights its potential as a target for immunotherapy [71], underlining its pivotal role in modulating tumour-immune interactions. The gene discussed is LILRB4; the disease is neoplasm.